Peptide Database

Peptide NameEKL1C

Function Ontology

Anticancer

Antimicrobial

Antiviral

Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2

Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition

Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor

Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic

Standard StatusStandard

Sequence Length40 amino acids

Chemical FormulaC211H328N46O70S2

DescriptionStandard

        NVTFLDLEYEMKKLEEAIKKLEESYIDLKELGTYEYGSGC
    

Molecular Weight4693.26 Da

Isoelectric Point (pI)4.39

Net Charge (pH 7.0)-5.23

Net Charge (pH 7.4) -5.48

Charge Density (pH 7.0) -0.1309

GRAVY Index-0.56

Hydrophobic Moment 0.75

Boman Index-0.03

Instability Index15.32

Aliphatic Index 87.75

Aromaticity 0.1250

Extinction Coeff. Reduced 5960.00

Extinction Coeff. Oxidized 5960.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

TPSA 1906.25

LogP -12.90

H-bond Donors 66.0

H-bond Acceptors 67.0

Rotatable Bonds 164.0

Heavy Atoms 329.0

Ring Count 5.0

Amide Bonds 40.0

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0029034 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonical stereochemical modification [Modified]

N-TermNone

C-TermChol

Other ModsChol

Bio-Activity Profile

Function

Antiviral Fusion inhibition Anti-coronavirus

TargetSARS-CoV-2 N435D pseudovirus

Activity0.135±0.013 μM

MethodIC50 (pseudovirus infection inhibition)

Half-LifeMammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h

PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/

RECORD: Rec_0029087 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonical conjugated peptide [Modified]

N-TermNone

C-TermChol

Other ModsC-terminal cholesterol conjugation

Bio-Activity Profile

Function

Antimicrobial Anti-SARS-CoV-2 Antiviral Anti-coronavirus Fusion inhibition

TargetSARS-CoV-2 pseudovirus; Caco-2 cells

Activity0.04±0.005 μM

MethodIC50 (pseudovirus infection inhibition)

PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2022 Apr;12(4):1652-1661. doi: 10.1016/j.apsb.2021.07.026. PMID: 34367893 PMID35087243;34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/

RECORD: Rec_0029972 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonical stereochemical modification [Modified]

N-TermNone

C-TermChol

Other ModsChol

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV-2 Fusion inhibition Anti-coronavirus

TargetSARS-CoV-2 D614G

Activity0.01177 μM

MethodIC50 (cell-cell fusion inhibition)

Half-LifeMammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h

PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/

RECORD: Rec_0036817 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonical conjugated peptide [Modified]

N-TermNone

C-TermChol

Other ModsC-terminal cholesterol conjugation

Bio-Activity Profile

Function

Antimicrobial Anti-SARS-CoV-2 Antiviral Anti-coronavirus Fusion inhibition

TargetSARS-CoV-2 F342L pseudovirus

Activity0.026±0.007 μM

MethodIC50 (pseudovirus infection inhibition)

PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2022 Apr;12(4):1652-1661. doi: 10.1016/j.apsb.2021.07.026. PMID: 34367893 PMID35087243;34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/

RECORD: Rec_0040995 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyHR2 fusion-inhibitory peptide

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitynoncanonical stereochemical modification [Modified]

N-TermNone

C-TermChol

Other ModsChol

Bio-Activity Profile

Function

Antiviral Anti-SARS-CoV-2 Fusion inhibition Anti-coronavirus

TargetSARS-CoV-2 spike-variant pseudovirus panel

Activity0.047±0.013 μM

MethodIC50 (pseudovirus infection inhibition)

Half-LifeMammalian: 1.4 h; Yeast: 3 min; E. coli: >10 h

PaperA highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. | Zhou J, Xu W, Liu Z, Wang C, Xia S, Lan Q, Cai Y, Su S, Pu J, Xing L, Xie Y, Lu L, Jiang S, Wang Q. | Acta Pharm Sin B. 2021 Aug 2. | DOI:10.1016/j.apsb.2021.07.026 | PMID:34367893 PMID34367893 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34367893/

FIRST PREV 1 2 3 4 ... 14 NEXT LAST

Showing 5 records · Page 2 of 14